Global Leukemia Therapeutics Market 2016-2020

  • ID: 3883908
  • Report
  • Region: Global
  • 110 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Arno Therapeutics
  • AstraZeneca
  • Bayer HealthCare
  • Bioge
  • MORE
About Leukemia

Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.

The analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- F. Hoffmann-La Roche
- Novartis
- Bristol-Myers Squibb
- AbbVie
- Teva Pharmaceuticals

Other prominent vendors
- Altor BioScience
- Amgen
- ARIAD Pharmaceuticals
- Arno Therapeutics
- Astex Pharmaceuticals
- AstraZeneca
- Baxter Healthcare
- Bayer HealthCare
- Bellicum Pharmaceuticals
- Biogen
- Boehringer Ingelheim
- BioLineRx
- Boston Biomedical
- Celator Pharmaceuticals
- Celgene
- CTI BioPharma
- Chroma Therapeutics
- Chugai Pharmaceutical
- Cyclacel Pharmaceuticals
- Daiichi Sankyo
- Eisai
- Emergent BioSolutions
- Erytech Pharma
- Fate Therapeutics
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- iDD biotech
- Immune Pharmaceuticals
- Immunomedics
- Infinity Pharmaceuticals
- Innate Pharma
- Jazz Pharmaceuticals
- Juno Therapeutics
- Karyopharm Therapeutics
- Ligand Pharmaceuticals
- MEDA Pharmaceuticals
- MedImmune
- Merck
- Midas Pharma
- Molecular Templates
- MorphoSys
- Nippon Shinyaku
- Novo Nordisk
- Onconova Therapeutics
- Ono Pharmaceuticals
- Orphan Europe
- Otsuka
- Pfizer
- Portola Pharmaceuticals
- Regeneron Pharmaceuticals
- Sanofi
- Sigma-Tau Pharmaceuticals
- Stemline Therapeutics
- Sunesis Pharmaceuticals
- TG Therapeutics
- TheraMAB
- Tolero Pharmaceuticals
- XEME Biopharma
- Xencor
- ZIOPHARM Oncology

Market drivers
- Technological advances in the monitoring of leukemia
- For a full, detailed list, view the full report

Market challenges
- Limitations associated with current therapeutic options
- For a full, detailed list, view the full report

Market trends
- Rise in the development of combination therapies
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Arno Therapeutics
  • AstraZeneca
  • Bayer HealthCare
  • Bioge
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Pipeline portfolio

PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: Market segmentation by disease type

PART 08: Global CLL therapeutics market
  • Market overview
  • Total addressable market for global CLL therapeutics
  • Vendors in the market
PART 09: Global ALL therapeutics market
  • Market overview
  • Vendors in the market
PART 10: Global AML therapeutics market
  • Market overview
  • Vendors in the market
PART 11: Global CML therapeutics market
  • Market overview
  • Vendors in the market
PART 12: Geographical segmentation
  • Global leukemia therapeutics market by geography 2015-2020
  • Leukemia therapeutics market in Americas
  • Leukemia therapeutics market in EMEA
  • Leukemia therapeutics market in APAC
PART 13: Market drivers
  • Special regulatory designations for drugs
  • Technological advances in the monitoring of leukemia
  • Application for expanded indication approvals
PART 14: Impact of drivers

PART 15: Market challenges
  • Complicated disease prognosis
  • Financial and infrastructural constraints
  • Limitations associated with current therapeutic options
  • Delay in diagnosis
PART 16: Impact of drivers and challenges

PART 17: Market trends
  • Rise in the development of combination therapies
  • Patient assistance programs
  • Focus on the identification of targets for the development of new therapies
PART 18: Vendor landscape
  • Competitive scenario
  • Other prominent vendors
PART 19: Key vendor analysis
  • F. Hoffmann-La Roche
  • Novartis
  • Bristol-Myers Squibb
  • AbbVie
  • Teva Pharmaceuticals
PART 20: Appendix
  • List of abbreviations
PART 21: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Timeline of development of leukemia drugs
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Key buying criteria for global leukemia therapeutics market 2015
Exhibit 05: Pipeline portfolio: Global CLL therapeutics market
Exhibit 06: Pipeline portfolio: Global CML therapeutics market
Exhibit 07: Pipeline portfolio: Global ALL therapeutics market
Exhibit 08: Pipeline portfolio: Global AML therapeutics market
Exhibit 09: Global leukemia therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 10: Distribution of people aged 60 years and over (millions)
Exhibit 11: Global leukemia therapeutics market 2015-2020 ($ billions)
Exhibit 12: Global leukemia therapeutics market segmentation: Growth cycle analysis
Exhibit 13: Five forces analysis
Exhibit 14: Segmentation of global leukemia therapeutics market by type of disease 2015
Exhibit 15: Global leukemia therapeutics market by type of disease 2015-2020
Exhibit 16: Global leukemia therapeutics market segmentation: Growth lifecycle analysis
Exhibit 17: Global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 18: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 19: Major vendors in the CLL therapeutics market 2015
Exhibit 20: Global ALL therapeutics market 2015-2020 ($ billions)
Exhibit 21: Major vendors in ALL therapeutics market 2015
Exhibit 22: Global AML therapeutics market 2015-2020 ($ millions)
Exhibit 23: Major vendors in global AML therapeutics market
Exhibit 24: Global CML therapeutics market 2015-2020 ($ billions)
Exhibit 25: Major vendors in global CML therapeutics market
Exhibit 26: Global leukemia therapeutics market by geography 2015-2020
Exhibit 27: Percentage share of global leukemia therapeutics market by geography 2015 and 2020
Exhibit 28: Global share of leukemia therapeutics market by geography 2015
Exhibit 29: Revenue of global leukemia therapeutics market by geography 2015-2020 ($ billions)
Exhibit 30: Revenue/growth outlook in different countries/regions 2015
Exhibit 31: Global leukemia therapeutics market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 32: Leukemia therapeutics market in different regions by type of disease
Exhibit 33: Opportunity analysis of leukemia therapeutics market in Americas
Exhibit 34: Percentage share of new cases of leukemia in US 2014
Exhibit 35: Hispanic population percentage in US total population
Exhibit 36: Leukemia therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 37: Opportunity analysis of leukemia therapeutics market in EMEA
Exhibit 38: Leukemia therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 39: Opportunity analysis of leukemia therapeutics market in APAC
Exhibit 40: Leukemia therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 41: Orphan designation pipeline drugs for leukemia
Exhibit 42: Breakthrough therapy designation drugs for leukemia
Exhibit 43: Expanded indication approval drugs in the treatment of leukemia
Exhibit 44: Impact of drivers
Exhibit 45: Cost of therapy for some leukemia drugs
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Combination therapies under development for the treatment of leukemia
Exhibit 48: Leukemia drugs with patient assistance programs
Exhibit 49: Key vendors ranking 2015
Exhibit 50: Geographical presence of key vendors in leukemia therapeutics market 2015
Exhibit 51: Competitive landscape of vendors in global leukemia therapeutics market 2015-2020
Exhibit 52: F. Hoffmann-La Roche: Profile
Exhibit 53: F. Hoffmann-La Roche: Strength analysis
Exhibit 54: F. Hoffmann-La Roche: Growth strategy matrix
Exhibit 55: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 56: F. Hoffmann-La Roche: YoY revenue and growth rate of Rituxan/MabThera 2013-2015 ($ billions)
Exhibit 57: F. Hoffmann-La Roche: Rituxan/MabThera geographic segmentation by revenue 2015
Exhibit 58: Novartis: Profile
Exhibit 59: Novartis: Strength analysis
Exhibit 60: Novartis: Growth strategy matrix
Exhibit 61: Novartis: Opportunity assessment
Exhibit 62: Bristol-Myers Squibb: Profile
Exhibit 63: Bristol-Myers Squibb: Strength analysis
Exhibit 64: Bristol-Myers Squibb: Growth strategy matrix
Exhibit 65: Bristol-Myers Squibb: Opportunity assessment
Exhibit 66: AbbVie: Profile
Exhibit 67: AbbVie: Strength analysis
Exhibit 68: AbbVie: Growth strategy matrix
Exhibit 69: AbbVie: Opportunity assessment
Exhibit 70: Teva Pharmaceuticals: Profile
Exhibit 71: Teva Pharmaceuticals: Strength analysis
Exhibit 72: Teva Pharmaceuticals: Growth strategy matrix
Exhibit 73: Teva Pharmaceuticals: Opportunity assessment
Exhibit 74: Teva Pharmaceuticals: YoY revenue and growth rate of TREANDA 2013-2015 ($ millions)

Exhibit 43: Expanded indication approval drugs in the treatment of leukemia

Exhibit 44: Impact of drivers

Exhibit 45: Cost of therapy for some leukemia drugs

Exhibit 46: Impact of drivers and challenges

Exhibit 47: Combination therapies under development for the treatment of leukemia

Exhibit 48: Leukemia drugs with patient assistance programs

Exhibit 49: Key vendors ranking 2015

Exhibit 50: Geographical presence of key vendors in leukemia therapeutics market 2015

Exhibit 51: Competitive landscape of vendors in global leukemia therapeutics market 2015-2020

Exhibit 52: F. Hoffmann-La Roche: Profile

Exhibit 53: F. Hoffmann-La Roche: Strength analysis

Exhibit 54: F. Hoffmann-La Roche: Growth strategy matrix

Exhibit 55: F. Hoffmann-La Roche: Opportunity assessment

Exhibit 56: F. Hoffmann-La Roche: YoY revenue and growth rate of Rituxan/MabThera 2013-2015 ($ billions)

Exhibit 57: F. Hoffmann-La Roche: Rituxan/MabThera geographic segmentation by revenue 2015

Exhibit 58: Novartis: Profile

Exhibit 59: Novartis: Strength analysis

Exhibit 60: Novartis: Growth strategy matrix

Exhibit 61: Novartis: Opportunity assessment

Exhibit 62: Bristol-Myers Squibb: Profile

Exhibit 63: Bristol-Myers Squibb: Strength analysis

Exhibit 64: Bristol-Myers Squibb: Growth strategy matrix

Exhibit 65: Bristol-Myers Squibb: Opportunity assessment

Exhibit 66: AbbVie: Profile

Exhibit 67: AbbVie: Strength analysis

Exhibit 68: AbbVie: Growth strategy matrix

Exhibit 69: AbbVie: Opportunity assessment

Exhibit 70: Teva Pharmaceuticals: Profile

Exhibit 71: Teva Pharmaceuticals: Strength analysis

Exhibit 72: Teva Pharmaceuticals: Growth strategy matrix

Exhibit 73: Teva Pharmaceuticals: Opportunity assessment

Exhibit 74: Teva Pharmaceuticals: YoY revenue and growth rate of TREANDA 2013-2015 ($ millions)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Arno Therapeutics
  • AstraZeneca
  • Bayer HealthCare
  • Bioge
  • MORE
New Report Released: – Leukemia Therapeutics Market 2016-2020

The author of the report recognizes the following companies as the key players in the leukemia therapeutics market: F. Hoffmann-La Roche, Novartis, Bristol-Myers Squibb, AbbVie, Teva Pharmaceuticals, Altor BioScience, Amgen, ARIAD Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene, CTI BioPharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, MEDA Pharmaceuticals, MedImmune, Merck, Midas Pharma, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.

Commenting on the report, an analyst from the research team said: “One of the key trends for market growth will be the rise in the development of combination therapies. Combination therapies for the treatment of leukemia were available only in the form of combination chemotherapy drugs. The some of the approved combinations are chlorambucil with prednisone, and cyclophosphamide with vincristine and prednisone for the treatment of CLL; a combination of cytarabine, daunorubicin, and etoposide for the treatment of AML; and a combination of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone for the treatment of ALL. Also, it has been observed that vendors are showing more interest in the development of combination therapies to treat various leukemias.”

According to the report, application for expanded indication approvals will be a key driver for market growth. There has been an increase in the R&D activities going on for the re-positioning of already marketed drugs for the new indications in the global leukemia therapeutics market. This concept of re-positioning came into practice in the early 1990s and is originate from the possibility of different diseases could be sharing common molecular pathways. The companies are conducting clinical trials to determine the effectiveness of the drugs in all such related indications. As this process of drug re-positioning leading to extended indication is low risk, high reward strategy, this should increase the scope of treatment and hence, help in the increased market penetration.

Further, the report states that financial and infrastructural constraints will be a major challenge for the market. The financial and infrastructural constraints associated with leukemia medications is high, especially in emerging nations. Most of the branded medications are not available in these regions as the companies have not received approvals. For instance, Venclexta, a product of AbbVie and F. Hoffmann-La Roche, received approval in April 2016 in the US, Europe, and Japan. The drug is yet to be launched in other regions. This reduces the accessibility of drugs for the individuals in these regions. Also, most of the branded therapies are costly. The high cost of therapy is a major factor resulting in treatment withdrawal by individuals. The R&D costs of developing such drugs are usually high. Therefore, manufacturers are forced to pass on these costs to the buyer. However, this inhibits the adoption of the drugs because the end-users perceive treatment costs as a burden.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- F. Hoffmann-La Roche
- Novartis
- Bristol-Myers Squibb
- AbbVie
- Teva Pharmaceuticals
- Altor BioScience
- Amgen
- ARIAD Pharmaceuticals
- Arno Therapeutics
- Astex Pharmaceuticals
- AstraZeneca
- Baxter Healthcare
- Bayer HealthCare
- Bellicum Pharmaceuticals
- Bioge
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll